New Post-Market Surveillance (PMS) regulations have taken effect across Great Britain, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
Similar Posts
Precautionary recall of blood pressure medication after packaging error
The MHRA has advised pharmacy and healthcare professionals to return all remaining stock to their suppliers
Find product information about medicines
How to get information including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs).
MHRA and NICE receive £2 million from Wellcome to improve safety and effectiveness of digital mental health technologies
Additional funding will allow the MHRA and NICE to continue developing clear, proportionate guidance for digital mental health technologies, supporting safer, more effective tools for people across the UK.
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.
Professor Bola Owolabi CBE: Creating the Climate for Health Equity
Exploring the MHRA’s transformational impact on access, experience, and outcomes.
Guidance: AI Airlock Background
Background information for MHRA AI Airlock launched in Spring 2024 and is the MHRA’s first regulatory sandbox for AI as a Medical Device (AIaMD) products.